Splenoportal Thrombosis After Splenectomy |
| Splenoportal
thrombosis represents one of the most important vascular complications
following splenectomy, emerging at the intersection of surgical
physiology, hematologic adaptation, and altered portal venous
hemodynamics. Although splenectomy remains a highly effective
therapeutic intervention for hematologic disease, portal hypertension,
trauma, and selected oncologic conditions, removal of the spleen
initiates profound systemic and regional circulatory changes that
predispose patients to thrombosis within the splenic, portal, and
mesenteric venous systems. The growing body of contemporary literature
has clarified that this complication is neither rare nor incidental but
rather a predictable biological consequence that demands structured
prevention, early recognition, and individualized management. The incidence of splenoportal thrombosis after splenectomy varies widely across clinical populations, reflecting differences in underlying disease, surgical indication, and surveillance strategies. Reported rates generally fall between approximately 5% and more than 20%, with higher values observed when routine postoperative imaging is performed rather than symptom-driven investigation. Some analyses suggest even broader ranges in high-risk populations, particularly those with portal hypertension or cirrhosis, underscoring that the true incidence may historically have been underestimated due to asymptomatic cases remaining undetected. Clinically, splenoportal thrombosis encompasses thrombosis involving the splenic vein, portal vein, superior mesenteric vein, or combinations of these vessels. The condition may present subtly, with abdominal pain, fever, nausea, or nonspecific malaise, but can progress to severe complications including intestinal ischemia, portal hypertension exacerbation, or hepatic dysfunction if untreated. Importantly, many patients remain asymptomatic during early stages, making imaging surveillance a critical component of postoperative care in selected populations. The pathophysiology of thrombosis after splenectomy is multifactorial and best understood through Virchow's triad: hypercoagulability, endothelial injury, and venous stasis. Splenectomy induces an immediate hematologic shift characterized by increased circulating platelets and procoagulant factors. Postoperative thrombocytosis occurs in a majority of patients and may reach extreme levels, although the direct relationship between platelet elevation and thrombosis remains complex. Some investigations demonstrate that elevated platelet counts correlate with thrombotic risk and may serve as predictive thresholds, while others suggest thrombosis occurs independently of thrombocytosis alone, indicating that platelet number is only one component of a broader prothrombotic environment. Beyond hematologic alterations, splenectomy dramatically modifies portal venous flow dynamics. Removal of the spleen eliminates a major inflow contributor to the portal system, producing abrupt changes in velocity patterns, pressure gradients, and wall shear stress. Computational modeling studies have demonstrated that areas of low wall shear stress increase after splenic vein ligation, creating localized hemodynamic environments conducive to clot formation. These changes are influenced by anatomical variables such as splenic vein diameter and portal venous geometry, suggesting that patient-specific vascular architecture plays a central role in thrombosis susceptibility. Surgical factors further modulate risk. Longer operative times, greater tissue manipulation, and technical complexity appear associated with higher thrombotic incidence, likely reflecting both inflammatory activation and prolonged venous stasis. Massive splenomegaly has emerged as one of the strongest predictors, particularly when specimen weight exceeds one kilogram. Large spleens are associated with increased venous caliber and altered postoperative flow redistribution, amplifying stasis within the portal circulation. Hematologic disorders such as myeloproliferative disease and myelofibrosis also confer elevated risk, combining intrinsic hypercoagulability with anatomical changes. Interestingly, the surgical approach itself—open versus laparoscopic—does not appear to independently determine thrombosis rates. While minimally invasive splenectomy offers reduced postoperative morbidity and shorter hospitalization, venous thrombotic incidence remains comparable between approaches. This observation reinforces the concept that thrombosis arises primarily from physiological consequences of splenic removal rather than technical modality. Temporal patterns of thrombosis formation provide additional insight. Most events occur within the first two to three postoperative weeks, although risk may persist for months. This delayed vulnerability highlights a critical limitation of traditional in-hospital prophylaxis strategies that terminate anticoagulation at discharge. Evidence increasingly suggests that extended thromboprophylaxis significantly reduces thrombotic events without substantially increasing bleeding complications. Patients receiving anticoagulation beyond hospitalization demonstrate markedly lower thrombosis rates compared with those treated only perioperatively. The role of anticoagulation has therefore become central in preventive strategies. Analyses evaluating postoperative anticoagulant therapy indicate that low–molecular weight heparin followed by oral anticoagulation can substantially decrease portal venous thrombosis incidence, particularly during the first six postoperative months. Importantly, concerns regarding excessive bleeding risk have not been consistently supported by clinical outcomes, suggesting that carefully selected prophylactic regimens are both effective and safe. Despite these advances, universal anticoagulation remains controversial. Not all patients carry equal risk, and indiscriminate therapy may expose low-risk individuals to unnecessary complications. Consequently, recent research has focused on risk prediction models designed to identify patients most likely to develop thrombosis. These models integrate clinical, laboratory, and anatomical variables, achieving moderate predictive accuracy with discrimination values generally indicating reliable but imperfect performance. While promising, many models suffer from limited external validation and retrospective design, emphasizing the need for individualized clinical judgment rather than reliance on algorithms alone. Emerging predictive approaches extend beyond clinical scoring systems into computational hemodynamics. Patient-specific modeling of portal venous circulation allows simulation of postoperative flow conditions, enabling identification of regions predisposed to thrombosis before surgery occurs. Such techniques represent a potential paradigm shift, moving prevention from reactive monitoring toward personalized preoperative risk stratification. Although still investigational, these tools highlight the growing convergence of surgery, imaging, and computational medicine in perioperative risk assessment. Diagnosis of splenoportal thrombosis relies primarily on imaging modalities. Contrast-enhanced computed tomography remains the most commonly used diagnostic tool, offering high sensitivity and anatomical detail, while Doppler ultrasonography provides a noninvasive alternative suitable for screening and follow-up. Given the frequency of asymptomatic presentation, routine imaging protocols have been advocated for high-risk patients, particularly during the early postoperative period when intervention is most effective. Management strategies are generally successful when thrombosis is detected early. Anticoagulation alone leads to recanalization or complete resolution in most patients, with low recurrence rates reported during long-term follow-up. Severe complications are uncommon when treatment is initiated promptly, reinforcing the importance of vigilance rather than aggressive intervention. Surgical or interventional radiologic procedures are rarely required and are typically reserved for cases complicated by bowel ischemia or extensive thrombosis. From a broader perspective, splenoportal thrombosis illustrates how removal of a single organ can disrupt systemic equilibrium. The spleen functions not only as an immunologic and hematologic organ but also as a regulator of portal circulation. Its absence transforms vascular dynamics, coagulation balance, and endothelial biology simultaneously. The postoperative state therefore represents a transitional physiological condition rather than a simple recovery phase, demanding targeted monitoring and adaptive management. Future directions in the field increasingly emphasize personalization. Integration of platelet kinetics, spleen size, disease etiology, operative characteristics, and hemodynamic modeling may eventually permit individualized prophylaxis protocols tailored to each patient's risk profile. Advances in imaging analytics and machine learning may further refine prediction accuracy, allowing clinicians to intervene selectively while minimizing overtreatment. In summary, splenoportal thrombosis after splenectomy is a common and clinically significant complication driven by complex interactions between hypercoagulability, altered venous flow, and patient-specific anatomical factors. Although often silent initially, it carries potential for severe morbidity if unrecognized. Contemporary evidence supports extended thromboprophylaxis in selected patients, early imaging surveillance, and prompt anticoagulation upon diagnosis. The evolution of predictive models and computational hemodynamic analysis signals a transition toward precision perioperative care. As understanding of postoperative portal physiology continues to expand, prevention and management strategies are likely to become increasingly individualized, improving outcomes while preserving the therapeutic benefits of splenectomy. Ultimately, recognition of splenoportal thrombosis as an expected physiological risk rather than an unpredictable complication represents the most important conceptual advance. Through systematic risk assessment, vigilant monitoring, and tailored prophylaxis, the complication can be anticipated, detected early, and treated effectively, transforming a once underappreciated hazard into a manageable aspect of modern splenic surgery. References: 1- Rottenstreich A, Kleinstern G, Spectre G, Da'as N, Ziv E, Kalish Y: Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes. World J Surg. 42(3):675-681, 2018 2- Szasz P, Ardestani A, Shoji BT, Brooks DC, Tavakkoli A: Predicting venous thrombosis in patients undergoing elective splenectomy. Surg Endosc. 34(5):2191-2196, 2020 3- Swinson B, Waters PS, Webber L, Nathanson L, Cavallucci DJ, O'Rourke N, Bryant RD: Portal vein thrombosis following elective laparoscopic splenectomy: incidence and analysis of risk factors. Surg Endosc. 36(5):3332-3339, 2022 4- Liao Z, Wang Z, Su C, Pei Y, Li W, Liu J: Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis. PLoS One. 18(8):e0290164, 2023 5- Wang T, Yong Y, Ge X, Wang J: A computational model-based study on the feasibility of predicting post-splenectomy thrombosis using hemodynamic metrics. Front Bioeng Biotechnol. 11:1276999, 2024 6- Huang L, Han Y, Li Y, Li J: Risk prediction models for portal vein thrombosis (PVT) in patients after splenectomy: A systematic review and meta-analysis. Eur J Surg Oncol. 51(10):110300, 2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|